Fig. 2. OVA CTL and Help peptide conjugated to CRX-527 promote DCs influx in the draining lymph node upon in vivo injection.

a Mice (n = 5 per group) were adoptively transferred with CFSE labeled OT-I or OT-II cells 24 h before intradermally receiving 2 nmol of OVA CTL or Help CRX-527 conjugates, or an equimolar mix of peptide and CRX-527. 48 h later the inguinal lymph nodes were harvested for analysis. b Representative dot plots for the gating of Mo-DCs and CD103+ dermal DCs in naïve versus vaccinated mice. Cells were pre-gated to exclude dead/CD19^neg/CD11c^neg/MHC class II^neg cells (c). Absolute count of Mo-DCs and XCR1+/CD103+ DCs in the inguinal lymph nodes (d). Representative histograms of CD86 expression in non-APCs (CD11c^neg), Mo-DCs or XCR1+/CD103+ DCs. e Fluorescence intensity of CD86 signal (GeoMean) in Mo-DCs and XCR1+/CD103+ DCs subsets upon vaccination. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparison test; *p < 0.05, *****p < 0.0001; data are displayed as mean ± SD.